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Cell-Penetrating Peptides: 
A Challenge for Drug Delivery
Sonia Aroui and Abderraouf Kenani
Abstract
Cell-penetrating peptide (CPP) is a term that describes relatively short amphipa-
thic and cationic peptides (7–30 amino acid residues) with rapid translocation 
across the cell membrane. They can be used to deliver molecular bioactive cargoes 
due to their efficacy in cellular internalization and also to their low cytotoxicity. 
In this review we provide an overview of the current approaches and describe the 
potential of CPP-based drug delivery systems and indicate their powerful promise 
for clinical efficacy.
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1. Introduction
A novel approach to overcome cell membrane impermeability and to deliver a 
large variety of particles and macromolecules into cells has been recently emerged, 
which is called cell-penetrating peptides (CPPs), also known as protein transduc-
tion domains (PTDs) [1, 2]. CPPs are generally short (up to 30 amino acids in 
length) water-soluble, cationic, and/or amphipathic peptides which make them 
promising vectors for therapeutic delivery, leading to a considerable amount of 
research focused on the intracellular delivery of drugs [3–5]. There are two principal 
types of CPPs that have been utilized for this purpose: (i) cationic CPPs, composed 
of short sequence of amino acids (arginine, lysine, and histidine). The indicated 
amino acids give the cationic charge to the peptide and permit its interaction with 
anionic motifs on the plasma membrane by a receptor-independent mechanism. (ii) 
amphipathic peptides, which have lipophilic and hydrophilic tails that are respon-
sible for a direct peptide translocation mechanism across the plasma membrane [6].
The most important characteristic of CPPs is that they are able to translocate the 
plasma membrane at low micromolar concentrations in vivo and in vitro without 
using any receptors and without causing any significant membrane damage [7, 8]. 
Other benefits of using CPPs for therapeutic delivery are the absence of toxicity as 
compared to other cytoplasmic delivery devices, such as liposomes, polymers, etc. 
[6]. The mechanism for the CPP-facilitated cellular uptake remains not clear and 
depends on cargo and cellular type [9]. Due to its high density of basic amino acid 
residues (Arg and Lys), the large charge at physiological pH excludes the passive 
diffusion of CPPs across the lipid bilayer. Furthermore, it seems that classical 
uptake mechanisms such as protein-based receptors and transporters are not 
involved. On the contrary, endocytosis was shown as a common uptake mechanism, 
but is controversial at the same time. For example, in a number of reports, CPP 
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uptake was not inhibited at 4°C or in the presence of inhibitors of endocytosis; in 
contrast, a capture of CPPs in the endocytotic vesicles was observed when soluble 
heparin sulfate was added [9, 10]. Many other studies indicate that aggregation of 
the cell surface glycosaminoglycan heparan sulfate (HS) is an important element 
in the uptake mechanism [2]. The challenge of the strategy using CPPs should take 
into consideration the size, stability, nonspecific versus specific associations, and 
potency versus toxicity that all play an important role for the selection of delivery 
systems [5].
2. History and origin of CPPs
The CPPs are initially discovered in 1965 when it was observed that histones 
and cationic polyamines such as polylysine stimulate the uptake of albumin by 
tumor cells in culture. It was shown that the conjugation of polylysine to albumin 
and other proteins enhances their transport into cells. Moreover, a comparison 
study of different homopolymers of cationic amino acids demonstrates that 
medium-length polymers of arginine enter cells more effective than similar-
length polymers composed of lysine, ornithine, or histidine [11]. In 1988, it was 
discovered that the human immunodeficiency virus type 1 (HIV-1) encoded 
trans-acting activator of transcription (Tat) peptide which also translocates cell 
membranes and gains intracellular mammalian cells [12, 13]. Covalently the con-
jugation of Tat peptide to proteins or fluorescent markers allowed these molecules 
to gain into the cell. A few years later, another discovery was followed when poly-
cationic peptide of natural (VP22 and AntP) and synthetic origin (transportan) 
was used for the delivery of genes, proteins, small exogenous peptide, or even 
nanoparticles. Furthermore, it was demonstrated that small domains in these 
peptides are often responsible for cellular entry [14]. Thus, these translocation 
sequences could be shortened to a few amino acids in comparison with the first 
Tat peptide, without affecting cell penetration efficiency [13]. Since that time, 
the list of synthetic CPPs has increased sharply, and the number continues to rise 
(Table 1). In the last decade, another peptide was described named maurocalcine 
(MCa), a 33 amino acid residue peptide that has been isolated from the venom of 
the Tunisian chactid scorpion Scorpio maurus palmatus. It folds according to an 
“inhibitor cystine knot” (ICK) motif and contains three disulfide bridges con-
nected by the following pattern: C1–C4, C2–C5, and C3– C6 [15]. MCa acts on 
ryanodine receptors resulting in pharmacological activation. These receptors are 
calcium channels located in the membrane of the endoplasmic reticulum. They 
control Ca2+ release from internal stores and therefore a large number of cell 
functions [16, 17].
This peptide possesses vector properties when coupled to fluorescent streptavi-
din. This complex was shown to enter various cell types within minutes and in all 
cell types tested, a common feature of CPPs. A variety of mutants of MCa were then 
designed in order to unravel the most active residues for its pharmacological and 
penetration activities (Figure 1) [18, 19].
3. Therapeutic applications of CPPs
3.1 CPP-cargo complex internalization mechanisms
Two distinct advances were shown to be used to bind CPPs to molecular cargoes. 
One process is non-covalently which connect CPP to its cargoes using electrostatic 
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Peptide Sequence Origin Cargoes
Protein transduction domain
Tat48-60 GRKKRRQRRRPPQ VIH-1 ADN, peptide, PKC inhibitor
Pénétratin RQIKIWFQNRRMKWKK Drosophila Antennapedia homeodomain HSP20 phosphopeptide
Chimeric peptides
Transportan GWTLNSAGYLLGKINLKALAALAKKIL Galanin + Mastoparan Protéine, PNA
Pep-1 KETWWETWWTEWSQPKKKRKV Rich domain of tryptophan + spacer + domain derived from 
virus SV40-NLS sequence of T antigène
Enzyme
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV Hydrophobic motif derived from HIV-1 gp41 + linker + domain 
derived from virus SV40-NLS sequence of T antigène
siARN,
oligo-nucléotides
CADY GLWRALWRLLRSLWRLLWRA Dérived from PPTG11, variant of JTS1 fusion protéin siARN
Peptide models
(Arg)x (RRRRR)X Synthetic peptide siARN, Cyclosporine A
MAP KLALKLALKALKAALKA Synthetic peptide Natural CPPs
Natural CPP
Maurocalcine GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR Scorpio maurus palmatus Doxorubicin
Table 1. 
Examples of four classes of CPPs and delivered cargoes. The list of cargo is not exhaustive and given for illustration. X = 7, 8, or 9 arginine residues.
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Figure 1. 
Example of origin of four CPPs: Maurocalcine, penetratin, tat, and polyarginine. Maurocalcine, penetratin, 
and tat are derived from natural sequences, but polyarginine was produced by de novo conception in order to 
obtain a good cellular penetration.
interactions, such as MPG and Pep-1, amphipathic peptides carriers, which link to 
cargoes beyond any cross linking or chemical changes [20]. The second approach is 
more frequent and uses a covalent relation between the two compounds. This means 
has been widely used by different teams and has demonstrated positive advances, 
especially with TAT, penetratin, or polyarginines [21].
Various mechanisms for CPP internalization have been suggested, but the exact 
one is still not well known. Yet, many data approve that the energy-dependent tool 
(endocytosis) and the energy-independent mechanism (direct translocation) or 
both are involved in the cellular uptake progress [22].
For direct penetration, various mechanisms have been described: the carpet-like 
model (membrane destabilization) [23] and the pore formation model (barrel-
stave) [24]. Positively charged CPPs interact with negatively charged membrane 
components like phospholipid bilayer or heparan sulfate. Such interaction is dwell-
ing on the first stage of all of these mechanisms, followed by destabilization of the 
membrane and finished by crossing of the CPP on the lipid membrane.
For endocytosis transduction or cellular digestion, pinocytosis, phagocytosis, 
and receptor-mediated endocytosis have been reported [25, 26]. A sum-up of CPP 
transduction systems is shown in Figure 2. In pinocytosis, the plasma membrane 
absorbs solutes, while in phagocytosis it takes great particles. In clathrin-mediated 
endocytosis, clathrin and also caveolin, which are receptor-mediated endocytosis 
and cover the intracellular part of the biomembranes, possess a key role in the 
uptake mechanism. These protein structures are pivotal for the membrane invagi-
nation and for the construction of the vesicles after bounding the extracellular 
molecule to the membrane receptor. Clathrin has a great diameter in comparison 
with caveolin-coated vesicles and was also considered as a selective route for the 
translocation of compounds into cells through specific receptors on the surface of 
the cell [27].
Many determinants influence the internalization process, such as the nature 
of CPP or the cell type, the cargo, and the experimental conditions (temperature 
and pH) [22].
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3.2 Delivery of chemotherapeutic agents
Chemotherapy used for treatment of cancer has a lot of defects because of the 
toxicity of the drugs to normal healthy cells and also to resistance developed by 
tumor cells to the anticancer drug [28]. The major inconveniences with used cancer 
chemotherapy are the absence of specificity target to tumor cells and thus poor 
antitumor effect. The challenge in cancer therapy is to know how to deliver a drug 
intact to the cytosol of every cancer cell, sparing healthy cells.
It was shown that polyarginines carry cargoes that exceed 500 Da by molecular 
electroporation across the cell membrane which may solve part of the drug deliv-
ery problem [29]. However, the use of well-chosen linkers and anions can help 
target cancer cells and contribute to successful conjugation process. For example, 
the CXC chemokine receptor 4 (CXCR4) is overexpressed in different types of 
cancer, including prostate, breast, colon, and small-cell lung cancer. Snyder et al. 
linked the CXCR4 receptor ligand, DV3, to two transducible anticancer peptides: a 
p53-activating peptide (DV3-TATp53C′) and a cyclin-dependent kinase 2 antagonist 
peptide (DV3-TAT-RxL). Treatment of tumor cells expressing the CXCR4 recep-
tor with either the DV3-TATp53C′ or DV3-TAT-RxL targeted peptides resulted in 
an enhancement of tumor cell killing compared with treatment with nontargeted 
parental peptides [30]. Furthermore, hypoxia-inducible factor-1 (HIF), the 
transcription factor central to oxygen homeostasis, is regulated via the oxygen-
dependent degradation domains (ODD) of its α isoforms (HIFα). The amino- and 
carboxyl-terminal sequences of ODD (NODD and CODD) were fused to TAT and 
injected into sponges implanted subcutaneously (s.c.) in mice by William et al. They 
demonstrated that this injection causes a markedly accelerated local angiogenic 
response and induction of glucose transporter-1 gene expression, thus opening 
additional therapeutic avenues for ischemic diseases [31].
In some cancer cells, such as melanoma (common eye cancers in adults), p53 
seems to be inhibited by overexpression of HDM2. A transducible peptide that 
inhibits HDM2 and Bcl-2 for their ability to induce tumor-specific apoptosis in 
Figure 2. 
CPP translocation mechanisms.
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these cells was tested [30]. In this study, it was demonstrated that the anti-Bcl-2 
peptide induced apoptosis in tumor cells but also caused variable levels of toxicity in 
normal cells and tissues. On the contrary, the anti-HDM2 peptide induced apoptosis 
in tumor cells, with little effect on normal cells in a therapeutic dose range. This 
peptide also caused regression of retinoblastoma in rabbit eyes, with minimal dam-
age to normal ocular tissues. They conclude that the inhibition of HDM2 may be a 
promising strategy for the treatment of uveal melanoma and retinoblastoma, and 
that strategy may be an effective technology for local delivery of anticancer therapy 
to the eye.
Most of the patients with sporadic renal cell carcinomas (RCCs) exhibit muta-
tion of the Hippel-Lindau (VHL) tumor suppressor gene. Conjugation of the pro-
tein transduction domain of HIV-TAT protein to the amino acid sequence (104–123) 
in the beta-domain of the VHL gene product (pVHL) arrested and then reduced 
proliferation and invasion of 786-O renal cancer cells in vitro. Besides, daily i.p. 
injections with the conjugate put off and, in some cases, caused partial regression of 
renal tumors that were implanted in the dorsal flank of nude mice [32].
The tumor suppressor gene p16INK4A, an inhibitor of cdk3 4, is often inacti-
vated via intragenic mutation, homozygous deletion, and methylation-associated 
transcriptional silencing in a large number of human cancers, mainly in pancreatic 
cancer. Treated animals with the p16-derived synthetic peptide coupled with the 
Antennapedia carrier sequence, in which we designated as Trojan p16 peptide, 
showed reduced AsPC-1 and BxPC-3 s.c. tumors, respectively. Thus, we conclude 
that Trojan p16 peptide system, a gene-oriented peptide coupled with a peptide 
vector, functions for experimental pancreatic cancer therapy [33].
Recently, it was shown by Sonia et al. that coupling doxorubicin (Dox) to three 
cell-penetrating peptides Tat, penetratin, and maurocalcine (Dox-CPPs) is a good 
strategy to overcome Dox resistance in MDA-MB 231 breast cancer cells and CHO 
cells (Figure 3) [3, 34]. We also reported that all conjugates are able to promote cell 
apoptosis in the breast cancer-resistant cells MDA-MB 231 at lesser concentration 
needed for Dox alone. Indeed, apoptosis death was shown to be correlated with 
ladder-internucleosomal degradation, chromatin contraction, caspase activation, 
Bad and Bax activation by oligomerization on the mitochondrial membrane, and 
liberation of cytochrome c. Despite the effective Bcl-2 overexpression in apoptosis 
induced by the Dox alone, such potency was shown to be insufficient in case of 
Dox-CPP-triggered cell apoptotic death. Otherwise, these results suggest that there 
are other apoptotic signaling pathways, independent of mitochondrial one, which 
are implicated in Dox-CPP apoptosis. Moreover, greater effectiveness of Dox when 
coupled to CPPs is not due only to its higher accumulation on the cells but also to 
the incitement of other signaling pathways. These pathways include death receptors 
and activation of the JNK pathway [4, 35].
Figure 3. 
Cellular internalization of Dox by MCa. MDA-MB231 cells treated with (a) RPMI, (B) Dox alone (red), and 
(C) Dox coupled to Dox at the same concentration (red).
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Another study led by Leslie Walker et al. showed that conjugated Dox to both 
ELP and SynB1 prevents tumor development in mice. In fact, conjugation of Dox to 
SynB1-ELP was more efficient in tumor inhibition under hyperthermic condition 
than Dox alone, which was twofold higher. Such conception was considered hope-
ful peptide candidates for drug delivery [36]. The anticancer activity of Dox was 
also enhanced when constructed a drug delivery system by developing 25 nm gold 
nanospheres (GNSs) conjugated to four α-helical CPPs [37].
A thermally sensitive quantum dot that exhibits an “on-demand” cellular uptake 
behavior via temperature-induced “shielding/deshielding” of CPP on the surface 
was synthesized. Poly(N-isopropylacrylamide) (PNIPAAm) and CPP were biotinyl-
ated at their terminal ends and co-immobilized onto the surface of streptavidin-
coated quantum dots (QDs-Strep) through biotin-streptavidin interaction. Namely, 
under a lower critical solution temperature (LCST), the hydrated PNIPAAm chains 
blocked CPP cellular uptake. This effect was broken down when the LCST was 
raised to allow CPP moieties to be exposed on the cell surface, leading to QD cel-
lular uptake.
Additionally, the “shielding/deshielding” temperature of CPP was also used for 
siRNA delivery system. Biotinylated siRNA was coupled to the surface of TSQDs. 
Indeed, the amount of corresponding gene silencing was increased due to the 
surface exposure of CPP within a rising temperature above the LCST [38].
4.  Optimization methods for CPP-mediated cancer therapy and 
diagnosis
Over the last decade, a great attention has been assigned to the importance of 
CPP on drug transportation of bioactive molecules in various preclinical studies. In 
fact, novel computational basics have been made in order to develop knowledge on 
CPPs [39].
Previously, different researchers have developed a few in silico algorithm 
approaches for CPP prediction (CPPpred) and screening to facilitate throughput 
CPP-based research. The in silico screening/prediction methods aimed on the use 
of scales of chemical characteristic, such as z-descriptors [40, 41]. It is generally 
followed by experimental validation to make it reliable with less cost and time-
consuming approach. Later on, other CPP prediction applied neural network (NN) 
strategies were developed and consist on introducing an N-to-1 NN. The network 
proceeds by a sequence of 5 to 30 amino acids in length, as input, and gives a predic-
tion of how probably each peptide is to be cell penetrating [42]. This CPPpred offers 
an advantage since it was developed with repetition-reduced training and test sets.
Over the years, the commitment therapeutic importance of CPPs motivated 
other teams to develop the first version of CPP database, i.e., CPPsite which sup-
ports broad information on the promising use of CPPs [43]. The CPPsite manually 
created database of 843 experimentally described CPPs. Each consulting gives us 
data of the peptide involving peptide sequence, peptide name, nature of peptide, 
origin, chirality, uptake efficiency, subcellular localization, etc. A deep area of user-
friendly tools has been integrated in this database like analyzing and browsing tools. 
Moreover, they have introduced other informations concerning peptide sequences 
such as secondary/tertiary structure and physicochemical properties of peptides.
This database version was then developed and updated as a CPPsite 2.0 and 
holds 1855 entries, including 1012 recent new entries [44]. The renovated version 
contains further data concerning chemically modified CPPs used on the in vivo 
model. In addition to other informations on delivered cargoes by CPPs (proteins, 
molecules, nanoparticles, DNA, RNA, etc.), secondary and tertiary structures of 
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natural and chemical CPPs (including CPP with D-amino acids) were also pre-
dicted in view of their important role in the functionality of CPPs and stored in 
the database. Numerous tools for information browse and analysis are combined in 
this database and considered as a useful resource since it is compatible for all users, 
including smartphone and tablet.
CPP prediction sites are a promising assist to the researchers to design cell pen-
etrating peptide, as well as making different modification and to investigate their 
effect on cell penetration potency [45].
5. Conclusion
The progressive and continuous application of CPPs shows that they are effi-
cient delivery vectors. Because of the need to ameliorate the drug delivery, a great 
number of CPP-based applications are still drawing the attention of researchers.
In this review, the current tendency in drug delivery by CPPs is summed up. 
Conjugation with CPP increases cell-surface affinity and eventual cellular uptake of 
bioactive molecules.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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